DigestRedComo funciona
Red
/
Empresas
Ka
No verificado

KalVista Pharmaceuticals, Inc.

Sobre qué escribimos

BiotecnologíaCienciaFarmacéuticaMedicina - VariosSalud

82 Comunicados de prensa

Ver todos los comunicados de prensa
04/03/2026
Mercado de valores
Finanzas
Salud
Biotecnología
Ciencia
Farmacéutica
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fuente
KalVista Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
02/03/2026
Eventos
Industria
Salud
Biotecnología
Sanidad
Medicina - Varios
Farmacéutica
KalVista Pharmaceuticals Presents New Data Highlighting High Patient Satisfaction and Evolving Treatment Trends with EKTERLY® (sebetralstat)
Fuente
KalVista Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
25/02/2026
Eventos
Web y redes sociales
Biotecnología
Salud
Ciencia
Farmacéutica
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
Fuente
KalVista Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
18/02/2026
Salud
Ciencia
Farmacéutica
KalVista Pharmaceuticals Announces Inclusion of EKTERLY® (sebetralstat) as a First-Line Therapy for Adolescents 12 and Older in International Pediatric HAE Guideline
Fuente
KalVista Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
12/02/2026
Salud
Biotecnología
Sanidad
Medicina - Varios
Farmacéutica
Eventos
Industria
KalVista Pharmaceuticals to Present EKTERLY® (sebetralstat) Data at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting
Fuente
KalVista Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
03/02/2026
Mercado de valores
Finanzas
Salud
Biotecnología
Ciencia
Farmacéutica
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fuente
KalVista Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
08/01/2026
Venta al público/Minorista
Industria
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
KalVista Pharmaceuticals Provides Update on Strong EKTERLY® Launch with Preliminary Fourth Quarter and Full Year 2025 Revenue Results
Fuente
KalVista Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
22/12/2025
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Industria
KalVista Pharmaceuticals Announces Approval of EKTERLY® (sebetralstat) in Japan, First and Only Oral On-demand Treatment for Hereditary Angioedema
Fuente
KalVista Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
10/11/2025
Web y redes sociales
Telefonía
Mercado de valores
Ciencia
Biotecnología
Farmacéutica
Sanidad
Salud
Medicina - Varios
KalVista Pharmaceuticals Provides Operational Update and Reports Third Quarter Financial Results
Fuente
KalVista Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
06/11/2025
Eventos
Industria
Salud
Biotecnología
Sanidad
Medicina - Varios
Farmacéutica
KalVista Pharmaceuticals Presents New Data Highlighting Patient Satisfaction with EKTERLY® (sebetralstat) and its Potential in Children Ages 2-11 at the ACAAI 2025 Annual Scientific Meeting
Fuente
KalVista Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0